Search Results
Your search for ,ARE matches 21644 pages
Showing 7151 - 7200Regional Council for a Stronger Society
In 2019, ASCO launched an Asia-Pacific Regional Council, a group of distinguished oncology leaders from countries in the Asia-Pacific region. The Council’s purpose is to advise ASCO on the needs of members in the region and facilitate and encourage member involvement in ASCO’s global activities....
NCCN Adds Tafasitamab-cxix to Its Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
MorphoSys and Incyte have announced that tafasitamab-cxix, a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, has been included in the latest National Comprehensive Cancer Network Clinical Practice Guidelines® (NCCN Guidelines®) in Oncology for B-Cell Lymphomas. Specifically,...
October Cancer Awareness Month: Patient Resources From ASCO
Are you looking to provide trusted education materials to your patients and their caregivers for October cancer awareness month? Cancer.Net, ASCO’s patient information website, and ASCO Answers patient education materials have everything you need to stock your practice and inform your patients....
Conquer Cancer Collaborates With Israel Cancer Research Fund for Career Development Award in Israel
Conquer Cancer®, the ASCO Foundation has joined forces with the Israel Cancer Research Fund (ICRF) to grant a 2020 Career Development Award (CDA) to a physician-scientist in Israel. The CDA supports early-career clinical and translational investigators during their first few years of faculty...
Cancer in My Community: Caring for Children With Cancer in Armenia
Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how providers work to care for people with cancer in their region. Why I Care for People With Cancer When you tell someone that you are a pediatric oncologist and treat children with cancer, the first...
Leading Cancer Treatment Recommendations From NCCN Available in Several Languages
The National Comprehensive Cancer Network® (NCCN®) has announced the availability of multiple non–English-language versions of the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for numerous high-incidence cancer types. These treatment recommendations can be accessed for free at...
Cancer Center at Brown University Established
The Corporation of Brown University has approved the establishment of the Cancer Center at Brown. The center takes a broad-spectrum approach to research, from working to understand how cancer develops, grows, and metastasizes, to developing new therapeutics for patients in a personalized way that...
COVID-19 Pandemic Delays Cancer Care and Strains Resources
Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to COVID-19 have generated a huge backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...
National Survey Shows Decline in Overall Youth E-Cigarette Use, Uptick in Use of Disposable Products
In september, 2020, the U.S. Food and Drug Administration (FDA), in partnership with the Centers for Disease Control and Prevention, released new data from the 2020 National Youth Tobacco Survey (NYTS). The results, published by Wang et al in Morbidity and Mortality Weekly Report (MMWR), showed 1.8 ...
Many Reasons to ‘Geriatricize’ Your Oncology Practice: Research Updates From ASCO20
“Older adults form the majority of patients with cancer.” For more than 3 decades now, almost every article, presentation, or discussion related to cancer and aging started with this statement. As I entered the field of geriatric oncology, I thought that by simply stating this fact, everyone would...
New Breast Cancer Agents and Concurrent Radiation: Risk or Benefit?
Most of the newer systemic treatments for breast cancer can be safely and effectively paired with radiation therapy—although there are some exceptions, according to Mylin A. Torres, MD, the Louisa and Rand Glenn Family Chair in Breast Cancer Research and Associate Professor of Radiation Oncology at ...
Neratinib in Previously Treated HER2-Positive Metastatic Breast Cancer: Point of View From the NALA Trial
Neratinib is an oral pan-HER tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) for two indications. The first is as adjuvant treatment of early-stage HER2-positive breast cancer following adjuvant trastuzumab therapy. The second is in combination with...
I’ve Turned My Pain Into a New Life Purpose
The first half of 2016 was arguably the most exciting of my life. My wife, Jaione, and I had decided to leave the United Kingdom and move with our two children, Andrew, then 14, and Alba, then 10, to Denver, where I was taking on a leadership role in corporate affairs for a brewery company. By the...
Never Say Never
She was elderly, slightly confused, and very, very worried. I was not quite sure why. It was a minor procedure—a routine angiogram, one of a dozen to be performed that morning. The risks were so small that the job of admitting her had been handed to me, then a final-year medical student, with a...
Eric P. Winer, MD, Recipient of Lifetime Achievement in Mentoring Award
In September 2020, Eric P. Winer, MD, was honored with the William Silen Lifetime Achievement in Mentoring Award, presented by the Office for Diversity, Inclusion & Community Partnership at Harvard Medical School. Dr. Winer is Professor of Medicine, Harvard Medical School, and Director of the...
Karmanos Receives $630,000 CATCH-UP Grant to Recruit Minority, Rural Patients to Clinical Trials
Researchers at the Barbara Ann Karmanos Cancer Institute have secured a 1-year, $630,000 grant from the National Cancer Institute (NCI) to help support the Institute’s clinical trials, which target underserved populations in Detroit and in the rural areas that Karmanos serves. The NCI P30 Cancer...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Botswana
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Botswana. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Early Cancer Experience Plants the Seed for a Career in Oncology to Grow for Joyce F. Liu, MD, MPH
As a young girl growing up in central New Jersey, Joyce F. Liu, MD, MPH, a medical oncologist specializing in gynecologic cancers at Dana-Farber Cancer Institute, Boston, dreamed of becoming an astronaut. However, she realized her fear of heights and propensity for motion sickness didn’t jive with...
IU Cancer Center Researcher Awarded $5.7 Million to Study Chemotherapy-Induced Hearing Loss, Toxicities
A researcher at the Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center has been awarded a 5-year, $5.7 million National Cancer Institute (NCI) grant to evaluate long-term health outcomes for patients with cancer who receive platinum-based chemotherapies. An internationally...
Irish Boy With His Scapula
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Antiseptic Era 1876–1900 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies
Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...
NYGC Launches Collaborative Cancer Genomics Research Projects Focused on Underserved Populations
Leading cancer scientists working with the New York Genome Center (NYGC) announced that grants are being awarded to fund six projects that address the role of ethnicity in several major cancer types, taking advantage of the diversity of patients being treated at health-care institutions throughout...
Sentinel Lymph Node Biopsy and Age-Related Mutations: Therapeutic and Predictive Implications in Melanoma
Findings from a study among patients with melanoma randomly assigned to observation following removal of a positive sentinel lymph node “strongly support the therapeutic effect of the sentinel lymph node biopsy in providing long-term regional nodal disease control in the large majority of...
City of Hope Leads Novel Clinical Trial to Treat Patients With Cancer and COVID-19
City of Hope is investigating an innovative treatment for patients with cancer and COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis that is inexpensive and has few serious side effects, in a new clinical trial. Patients treated for cancer in the past 2 years...
Avapritinib Produces High Response Rate in Advanced PDGFRA D842V–Mutant GIST
As reported inThe Lancet Oncology by Michael C. Heinrich, MD, of the VA Portland Health Care System and the Oregon Health & Science University Knight Cancer Institute, and colleagues, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a high...
Expert Point of View: Christopher Anker, MD
Christopher Anker, MD, a radiation oncologist at The University of Vermont Medical Center and Associate Professor at the Larner College of Medicine at the University of Vermont, Burlington, told The ASCO Post that although the benefit to overall survival disappeared with time likely due to a power ...
Expert Point of View: George J. Chang, MD, MS, FACS, FASCRS
George J. Chang, MD, MS, FACS, FASCRS, of the Department of Surgical Oncology at The University of MD Anderson Cancer Center, told The ASCO Post that although adjuvant therapy in stage II disease has been shown to improve outcomes in patients with certain high-risk features, “the benefits are...
Corticosteroids Improve Survival in Critically Ill Patients With COVID-19, According to International Trial
In a demonstration of global collaboration, clinician-scientists have pooled data from 121 hospitals in 8 countries to find that inexpensive, widely available steroids may improve the odds that very sick patients with COVID-19 will survive the illness. The findings were made through the Randomized...
Azacitidine Tablets for Continued Treatment in Acute Myeloid Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 1, 2020, azacitidine tabletswere approved...
Expert Point of View: David Scott, MBChB, PhD
“In 2015, papers showed that ctDNA could suggest relapse noninvasively in serial plasma samples. In those studies, ctDNA was positive prior to relapse detected by computed tomography scans,” explained session moderator David Scott, MBChB, PhD, of the Center for Lymphoid Cancer, BC Cancer,...
Applications of Circulating Tumor DNA Liquid Biopsy Continue to Expand in Lymphomas
Liquid biopsies using circulating tumor DNA (ctDNA) have the potential to personalize medicine for patients with lymphoma, going beyond traditional markers and risk factors to provide dynamic assessments over time. Expanded applications of ctDNA liquid biopsy beyond diagnosis include early response ...
World Gynecologic Oncology Awareness Day: Turning the World Purple
Advocates for patients with cancer and medical professionals in more than 20 countries planned activities for World Gynecologic Oncology Day (World GO Day). A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of Gynaecological Cancer Advocacy Groups...
Expert Point of View: Christopher Flowers, MD
Commenting on this presentation, session moderator Christopher Flowers, MD, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston, said: “The treatment of adolescent and young adult patients with lymphoma remains a considerable challenge. The...
Disparities and Incidence of Late Effects of Treatment for AYA Lymphoma Survivors
The late effects of adolescent and young adults (AYA) with lymphomas are considerable and have not been given much attention, according to Theresa Keegan, MD, of the University of California at Davis. “Lymphoma is one of the most commonly occurring malignancies in AYAs,” she stated. “The 5-year...
The New Face of Medical Visits
“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...
Meta-analyses of Quality of Life in Patients Treated With Checkpoint Inhibitors
Findings from two meta-analyses designed to summarize quality-of-life data on patients receiving immune checkpoint inhibitor therapy for cancer were presented at the ESMO Virtual Congress 2020 (Abstract 1568O). These meta-analyses found that patients receiving immune checkpoint inhibitors had...
Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients
A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...
AACR Releases 10th Edition of Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 10th edition of its annual Cancer Progress Report. The report highlights how cancer research, largely supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI), is...
Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to...
Does Radical Hysterectomy Improve Survival in Patients With Cervical Cancer and Intraoperative Detection of Positive Lymph Nodes?
No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom a radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of positive pelvic lymph nodes. These...
Study Examines Combined Impact of Aspirin, Metformin, and Statins on Lung Cancer Risk
Combined use of aspirin, metformin, and statins may be associated with decreased lung cancer incidence and mortality, according to a study published by Kang et al in the Journal of Thoracic Oncology. Study Methods The aim of this study was to investigate the associations of the three agents with...
Early-Phase Trial Explores Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Genitourinary Malignancies
In a phase I trial reported in the Journal of Clinical Oncology, Andrea B. Apolo, MD, and colleagues found that the combination of cabozantinib and nivolumab, as well as the combination of cabozantinib/nivolumab plus ipilimumab, produced durable responses in patients with metastatic urothelial...
Can Drinking Coffee Daily Improve Survival in Patients With Advanced Colorectal Cancer?
In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and reduced risk of disease progression, according to findings reported by Mackintosh et al in JAMA Oncology. The findings, based on data from a large...
Impact of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy on Rates of Breast‑Conserving Surgery
“Studies that have compared neoadjuvant endocrine therapy with neoadjuvant chemotherapy have shown low pathologic complete response rates with both approaches. However, the rates of breast-conserving surgery have been shown to be slightly higher with neoadjuvant endocrine therapy,” Kelly Hunt, MD,...
New Report Focuses on Cancer Statistics in Adolescents and Young Adults
A new report examining cancer in adolescents and young adults (AYAs, defined as diagnoses occurring between the ages of 15 and 39) provides updated estimates of the contemporary cancer burden in this age group, with predictions that 89,500 cases and 9,270 deaths will occur in this group in 2020 in...
First-Line Checkpoint Inhibitors May Improve Survival in Gastroesophageal Cancers
Immune therapy for advanced gastroesophageal cancer has taken a leap forward by showing its value in the first-line setting, according to two studies in which nivolumab and pembrolizumab, both given with chemotherapy, significantly improved overall survival vs chemotherapy alone. The studies,...
Abemaciclib Plus Endocrine Therapy May Reduce Recurrence in Early Breast Cancer: monarchE Trial
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has improved outcomes in patients with early breast cancer when combined with standard endocrine therapy, Stephen Johnston, MD, PhD, and colleagues reported at the ESMO Virtual Congress 2020 (Abstract LBA5_PR)....
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...
World Gynecologic Oncology Awareness Day (World GO Day): September 20
Patient advocates and medical professionals in more than 20 countries have come together for the second annual World Gynecologic Oncology Day (World GO Day), taking place today, September 20. A project of the European Society of Gynaecological Oncology (ESGO) and the European Network of...
